




18th Annual Phase II Symposium April 12, 2013 Activity Eval.

1. Please identify yourself:

		Response Percent	Response Count
MD/DO		25.0%	7
Nurse		42.9%	12
Other Healthcare Professional		32.1%	9
		answered question	28
		skipped question	2

2. This activity helped me achieve the following objectives: (5=Strongly Agree, 1=Strongly Disagree)

	5	4	3	2	1	Rating Average	Rating Count
Understand of the effects of use of novel experimental agents	70.0% (21)	23.3% (7)	6.7% (2)	0.0% (0)	0.0% (0)	4.63	30
Assimilate requirements of new studies	31.0% (9)	58.6% (17)	10.3% (3)	0.0% (0)	0.0% (0)	4.21	29
Review synthesized data from completed studies	53.3% (16)	43.3% (13)	3.3% (1)	0.0% (0)	0.0% (0)	4.50	30
Review strategies to increase the availability of novel anti-cancer agents	51.7% (15)	34.5% (10)	13.8% (4)	0.0% (0)	0.0% (0)	4.38	29
Discuss the novel investigational agents available from the National Cancer Institution	56.7% (17)	40.0% (12)	3.3% (1)	0.0% (0)	0.0% (0)	4.53	30
Discuss the management options of rare tumor types	41.4% (12)	51.7% (15)	3.4% (1)	3.4% (1)	0.0% (0)	4.31	29
Discuss the advances in the use of chemo - and targeted therapies for cancer	65.5% (19)	31.0% (9)	3.4% (1)	0.0% (0)	0.0% (0)	4.62	29
Describe the rational for and results of studies that include the new targeted agents for the treatment of patients with advanced and rare diseases	75.9% (22)	17.2% (5)	6.9% (2)	0.0% (0)	0.0% (0)	4.69	29
answered question							30
skipped question							0

3. How confident are you in your ability to: (5=Highly Confident, 1=Not Confident at All)

	5	4	3	2	1	Rating Average	Rating Count
Understand of the effects of use of novel experimental agents	27.6% (8)	55.2% (16)	17.2% (5)	0.0% (0)	0.0% (0)	4.10	29
Assimilate requirements of new studies	18.5% (5)	74.1% (20)	7.4% (2)	0.0% (0)	0.0% (0)	4.11	27
Review synthesized data from completed studies	34.5% (10)	55.2% (16)	10.3% (3)	0.0% (0)	0.0% (0)	4.24	29
Review strategies to increase the availability of novel anti-cancer agents	22.2% (6)	55.6% (15)	18.5% (5)	3.7% (1)	0.0% (0)	3.96	27
Discuss the novel investigational agents available from the National Cancer Institution	21.4% (6)	57.1% (16)	21.4% (6)	0.0% (0)	0.0% (0)	4.00	28
Discuss the management options of rare tumor types	28.6% (8)	42.9% (12)	28.6% (8)	0.0% (0)	0.0% (0)	4.00	28
Discuss the advances in the use of chemo - and targeted therapies for cancer	50.0% (14)	39.3% (11)	10.7% (3)	0.0% (0)	0.0% (0)	4.39	28
Describe the rational for and results of studies that include the new targeted agents for the treatment of patients with advanced and rare diseases	42.9% (12)	42.9% (12)	14.3% (4)	0.0% (0)	0.0% (0)	4.29	28
answered question							29
skipped question							1






4. Did this activity: (5=Completely, 1=Not at All)

	5	4	3	2	1	Rating Average	Rating Count
Address the competencies/attributes relevant to your specialty?	57.1% (16)	35.7% (10)	7.1% (2)	0.0% (0)	0.0% (0)	4.50	28
Equip you with information to overcome barriers to treatment?	48.1% (13)	37.0% (10)	11.1% (3)	3.7% (1)	0.0% (0)	4.30	27
Increase your competence, skills, and/or performance in providing improved patient care?	55.6% (15)	25.9% (7)	14.8% (4)	3.7% (1)	0.0% (0)	4.33	27
Present the material in a format appropriate to the topic?	58.6% (17)	34.5% (10)	6.9% (2)	0.0% (0)	0.0% (0)	4.52	29
answered question							29
skipped question							1

5. After participating in this activity, will you make any changes in your practice? (Please describe a specific change you will make to your practice).

	Response Count
	12
answered question	12
skipped question	18






6. Are there any barriers or problems that might prevent you from implementing changes in your practice? Please select all that apply

		Response Percent	Response Count
Lack of evidence-based guidelines		7.7%	1
Organizational/ institutional barriers		38.5%	5
Limited time		7.7%	1
Insurance/ financial		61.5%	8
Increased workload		15.4%	2
Other		0.0%	0

(please indicate below) 5






answered question	13
skipped question	17

7. How much of the content presented at this meeting was new to you?



		Response Percent	Response Count
0-20%		3.4%	1
21-40%		27.6%	8
41-60%		34.5%	10
61-80%		27.6%	8
81-100%		6.9%	2

answered question	29
skipped question	1

8. How many years have you been in practice?

		Response Percent	Response Count
0 – 5 years		25.0%	7
6 – 15 years		32.1%	9
16 – 25 years		28.6%	8
26 – 30 years		7.1%	2
31+ years		7.1%	2
answered question			28
skipped question			2

9. Did any of the presentations contain pharmaceutical company or medical device manufacturer bias?

		Response Percent	Response Count
Yes		3.4%	1
No		96.6%	28
Comments (please be as specific as possible):			0
answered question			29
skipped question			1

10. List future CME topics that would be of value to you, and please be specific:

	Response Count
	4
answered question	4
skipped question	26

**Page 2, Q1. After participating in this activity, will you make any changes in your practice?
(Please describe a specific change you will make to your practice).**

1	NA	Jul 15, 2013 12:14 PM
2	No	Jul 15, 2013 12:09 PM
3	NA	Jul 15, 2013 12:08 PM
4	Will (illegible) certain subtypes of (illegible) for (illegible) mutation.	Jul 15, 2013 12:06 PM
5	N/A	Jul 15, 2013 11:56 AM
6	N/A	Jul 15, 2013 11:55 AM
7	Enroll in trials	Jul 15, 2013 11:50 AM
8	N/A	Jul 15, 2013 11:47 AM
9	Review potential for false positives regarding HPV + In H/N	Jul 15, 2013 11:36 AM
10	Would like an implement standard testing on melanoma - universal (illegible) testing on all cutaneous tumors and testing on an esophageal ca for HPV	Jul 15, 2013 11:34 AM
11	Offer specific trials to pts.	Jul 15, 2013 11:30 AM
12	We will continue to offer novel clinical trials to our patients.	Jul 15, 2013 11:20 AM

**Page 2, Q2. Are there any barriers or problems that might prevent you from implementing changes in your practice?
Please select all that apply**

1	N/A	Jul 15, 2013 11:56 AM
2	N/A	Jul 15, 2013 11:55 AM
3	N/A	Jul 15, 2013 11:47 AM
4	Always an issue	Jul 15, 2013 11:26 AM
5	N/A	Jul 15, 2013 11:24 AM

Page 2, Q6. List future CME topics that would be of value to you, and please be specific:

1	ASCO updates on each tumor site; How to improve patient accural/recuntinent; compliance in clinical trials, quality of life in cl trials	Jul 15, 2013 12:14 PM
2	Circulating tumor DNA	Jul 15, 2013 12:06 PM
3	-Advanced practices in data monitoring	Jul 15, 2013 11:47 AM
4	Ovarian cancer treatments for (illegible)	Jul 15, 2013 11:30 AM